Testing a new injection given less often for hard-to-treat blood cancer

This trial is testing a medication called elranatamab, given as an injection under the skin, for patients whose multiple myeloma (a blood cancer) has returned or stopped responding to at least three different types of previous treatments. The study is designed to see if this medication works well when given at home as an outpatient, and whether the injection can be given less and less frequently over time as the disease improves.

Multiple myeloma is a serious blood cancer that often comes back or stops responding to standard treatments, leaving patients with limited options. This trial is testing whether this medication can offer hope to those with hard-to-treat disease, and whether giving it less frequently could make treatment easier and safer by reducing hospital visits and infection risk.